Reimbursed Care Access in Uganda

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. This follows Uganda's recent move to strengthen narcotics and psychotropic controls in the Narcotics and Psychotropic Substances reform process passed by Parliament in 2023 which reasserts strict controls and penalties for most psychotropic substances. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Uganda's recent narcotics reform emphasis and standard national drug control practices mean MDMA is not available through clinical care or reimbursement outside tightly regulated trials. #

There is no public record of regulatory approval or reimbursement authorization for esketamine (Spravato) in Uganda; the National Drug Authority (the national regulator responsible for approving medicines and supervising importation and distribution) does not list esketamine as an approved or nationally distributed product in accessible registries. Consequently esketamine is not available through public reimbursement programmes and would only be accessible, if at all, via private importation or as part of an approved clinical trial (no public trial registry entries or approvals for routine use are publicly documented). # #

Ketamine is approved and widely used in Uganda primarily as an anaesthetic and emergency/field anaesthetic agent and is listed on the WHO Model List of Essential Medicines, which many low- and middle-income country procurement systems reference when planning essential medicines supply. #

Regulatory and delivery context: Uganda’s health system (via National Medical Stores and other public procurement agencies and mission/NGO supply chains) supplies injectable anaesthetics used in government and mission hospitals; multiple surveys and facility assessments report ketamine as consistently available across district and regional hospitals and as the common induction or sole anaesthetic agent in many facilities, particularly resource-limited settings in Uganda. This reflects clinical practice where ketamine is a mainstay for general anaesthesia, emergency surgery, and obstetric indications where other agents or monitoring are limited. #

Insurance / reimbursement: There is no nationally structured, diagnosis‑specific reimbursement for ketamine as a mental‑health or psychiatric intervention; rather ketamine is procured and reimbursed within the general essential medicines and hospital pharmaceuticals procurement and hospital service budgets (public hospitals, mission hospitals and private clinics procure injectable ketamine for anaesthesia through National Medical Stores, Joint Medical Store and private suppliers). There is no public programme reimbursing ketamine for psychiatric indications (e.g., treatment‑resistant depression) through established national mental‑health formularies or insurance — any off‑label psychiatric use would be exceptional, conducted in private practice or within approved research, and not systematically reimbursed. # #

Regional/state variation: Uganda is a unitary state; availability differences are operational (urban Kampala hospitals and referral centres are more consistently stocked and staffed, while many rural/district hospitals may rely on ketamine as the primary anaesthetic due to resource constraints). National procurement channels (National Medical Stores and Joint Medical Store) determine distribution; local availability therefore reflects stock and supply chain rather than differing legal frameworks.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. National narcotics controls introduced and reinforced in recent reforms do not provide pathways for routine medical or reimbursed access to DMT outside licensed research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. No documented regulatory pathway exists in Uganda for licensed medical use or reimbursement of 5‑MeO‑DMT. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no authorised medical or reimbursement pathway for ibogaine in Uganda. #

Because ayahuasca contains DMT (a controlled tryptamine), it is treated as a prohibited psychotropic preparation under strong national narcotics control frameworks; there is no authorised medical or reimbursed access outside approved research. Use in religious or traditional contexts is not established as legally exempt under national law. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Indigenous cactus use or ritual exemptions are not codified as legal exceptions in Uganda's national statute reforms; mescaline-containing preparations are not reimbursed or authorised for clinical use. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Synthetic phenethylamines (2C‑series) are encompassed by broad psychotropic substance prohibitions under Uganda's narcotics control framework and are not available through medical or reimbursement channels. #